Human papillomavirus vaccination coverage among adolescent girls, 2007-2012, and postlicensure vaccine safety monitoring, 2006-2013 - United States

Morbidity and Mortality Weekly Report

Volumn 62, Issue 29, 2013, Pages 591-595

  Stokley, Shannon ^a   Robinette Curtis, C ^a   Jeyarajah, Jenny ^a   Harrington, Theresa ^b   Gee, Julianne ^b   Markowitz, Lauri ^c  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b National Center for Enteric Zoonotic and Infectious Diseases   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CHILD; FEMALE; HUMAN; IMMUNIZATION; PAPILLOMAVIRUS INFECTION; POSTMARKETING SURVEILLANCE; SAFETY; STATISTICS; UNITED STATES; VACCINATION;

ADOLESCENT; ADULT; CHILD; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRODUCT SURVEILLANCE, POSTMARKETING; SAFETY; UNITED STATES; VACCINATION; YOUNG ADULT;

EID: 84880799500     PISSN: 01492195     EISSN: 1545861X     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. CDC. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2007;56(No. RR-2).
2. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA 2009;302:750-757.
3. CDC. National and state vaccination coverage among adolescents aged 13-17 years-United States, 2011. MMWR 2012;61:671-677.
4. Satterwhite CL, Torrone E, Meites E, et al. Sexually transmitted infections among US women and men: prevalence and incidence estimates, 2008. Sex Transm Dis 2013;40:187-193.
5. Markowitz LE, Hariri S, Lin C, et al. Reduction in HPV prevalence among young women following vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013;208:385-393.
6. Flagg EW, Schwartz R, Weinstock H. Prevalence of anogenital warts among participants in private health plans in the US, 2003-2009: potential impact of HPV vaccination. Am J Public Health 2013;103:1428-1435.
7. Ali H, Donovan B, Wand H, et al. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ 2013;346:f2032.
8. Baandrup L, Blomberg M, Dehlendorff C, Sand C, Anderson KK, Kjaer SK. Significant decrease in the incidence of genital warts in young Danish women after implementation of a national human papillomavirus vaccination program. Sex Transm Dis 2013;40:130-135.
9. Daley MF, Crane LA, Markowitz LE, et al. Human papillomavirus vaccination practices: a survey of US physicians 18 months after licensure. Pediatrics 2010;126:425-433.
10. Oster NV, McPhillips-Tangum CA, Averhoff F, Howell K. Barriers to adolescent immunization: a survey of family physicians and pediatricians. J Am Board Fam Pract 2005;18:13-19.